The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Timeframe: At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1]
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Timeframe: At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Timeframe: At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Timeframe: At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Timeframe: At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11